Carregant...
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease
Impaired bone formation contributes to the lack of bone healing in multiple myeloma and there is a need for agents with bone anabolic properties to reverse the bone deficit in patients. Bortezomib, a proteasome inhibitor with antitumour efficacy in myeloma patients, enhanced new bone formation in mo...
Guardat en:
| Publicat a: | Br J Haematol |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2007
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4482356/ https://ncbi.nlm.nih.gov/pubmed/17910634 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2007.06829.x |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|